title: Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation.
abstract: Lung transplant (LT) recipients among solid organ transplant recipients are at high risk for cytomegalovirus (CMV) infections. We evaluated the effect of CMV-Immunoglobulins (CMV-IG) (Cytotect Biotest) on CMV pneumonia diagnosed in 303 follow-up transbronchial biopsies (TBB) of lung transplant recipients. 24 patients (control group, 155 TBB from 1999 to 2002) received acyclovir for 24 months and 33 recipients (study group, 148 TBB from 2003 to 2008) received a combined CMV prophylaxis consisting of CMV-IG (Cytotect Biotest) for 12 months and a short Ganciclovir or Valganciclovir therapy from 21th to 42th postoperative day followed by acyclovir up to 24 months. In our study the percentage of pneumonia at first month TBB was similar in the study group vs the control group, 9.1% (3/33) vs 8.3% (2/24), p=0.9 ns, but after the first month the percentage was significantly lower in the study group in the first year at follow-up TBB, 1% (1/99) vs 6.4% (5/78), p=0.048, and in first two years follow-up TBB, 0.8% (1/122) vs 6.5% 8/124), p=0.018 (STATISTICAL ANALYSIS: Chi-square test for proportion differences). Our data suggest a strong efficacy of CMV-IG prophylaxis in reducing CMV pneumonia after first month in lung transplant recipients.
authors.affiliation: Divisions of Respiratory Diseases Cardiothoracic Department San Giovani Battista, Molinette Hospital Corso Bramante, Torino. psolidoro@molinette.piemonte
authors.forename: Paolo
authors.initials: P
authors.lastname: Solidoro
authors.forename: Luisa
authors.initials: L
authors.lastname: Delsedime
authors.forename: Cristina
authors.initials: C
authors.lastname: Costa
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Bergallo
authors.forename: Daniela
authors.initials: D
authors.lastname: Libertucci
authors.forename: Enrico
authors.initials: E
authors.lastname: Ruffini
authors.forename: Mauro
authors.initials: M
authors.lastname: Rinaldi
authors.forename: Sergio
authors.initials: S
authors.lastname: Baldi
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D003587:Cytomegalovirus / Q000187:drug effects / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D016040:Lung Transplantation / Q000009:adverse effects*; D011024:Pneumonia, Viral / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D011183:Postoperative Complications / Q000517:prevention & control* / Q000628:therapy / Q000821:virology; D013997:Time Factors; D016896:Treatment Outcome; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D007136:Immunoglobulins; D000077562:Valganciclovir; D015774:Ganciclovir; D000212:Acyclovir